Business Wire

KANEKA: “Development of Polymer Synthesis Technology by Microorganisms using CO2 as Direct Raw Material” selected as a NEDO Green Innovation Fund Project”


Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka; hereinafter "Kaneka"), Bacchus Bio innovation Co., Ltd (Headquarters: Kobe-city, Hyogo; President: Mikio Tanji; hereinafter "Bacchus"), JGC Holdings Corporation (Headquarters: Yokohama-city Kanagawa; Chairman and CEO: Masayuki Sato; hereinafter "JGC HD"), and Shimadzu Corporation (Headquarters: Kyoto-city, Kyoto; President: Yasunori Yamamoto; hereinafter "Shimadzu") have announced that the proposal of a joint project, “Development of Polymer Synthesis Technology by microorganisms using CO2 as direct raw material (hereinafter referred to as ‘the Project’)” had been selected by the "Green Innovation Fund Project*1 / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material” as a planned implementation sponsored by the New Energy and Industrial Technology Development Organization (NEDO).

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

(Figure 1) Recycling-oriented Biomanufacturing Technology (Graphic: Business Wire)

This project will contribute to the realization of carbon recycling in the "Green Growth Strategy Through Achieving Carbon Neutrality in 2050" formulated by the Ministry of Economy, Trade and Industry with related ministries and agencies on December 25, 2020 (revised on June 18, 2021). The goal of the project is to realize recycling-oriented biomanufacturing technology that does not depend on fossil resources by developing microorganisms that produce biodegradable polymers from CO2 and developing production process technology, combining the knowledge and technology that the four companies have cultivated over the years.

During the project period (FY2023 to FY2030), the following three themes will be addressed.

  • Establishment of a gas fermentation biofoundry*2 using CO2 as a raw material (Bacchus and Shimadzu)
  • Development and improvement of biopolymer-producing microorganisms (Kaneka)
  • Development and demonstration of production technology using microorganisms capable of producing substances from CO2 (Kaneka, JGC HD, Shimadzu)

[ Kaneka ]
Kaneka is the first company in the world to successfully commercialize KANEKA Biodegradable Polymer Green PlanetTM ("Green Planet"), which is produced by microorganisms from vegetable oil and other raw materials. In this project, based on the synthetic microbiology and polymer production, processing technologies it has cultivated to date, Kaneka will develop new microorganisms that produce Green Planet directly from CO2, and will also launch a semi-commercial plant to conduct production demonstration for Green Planet industrialization. In addition, we will lead this project as the managing company.

[ Bacchus ]
Bacchus is a data-driven biofoundry company. Bacchus aims to drastically shorten the breeding time of smart cells*3 by upgrading the breeding platform consolidating its proprietary technologies. By utilizing its own digital technology, Bacchus will design cells optimized for gas fermentation and create a variety of species. In addition, they will introduce and utilize data from a high-throughput evaluation system jointly developed with Shimadzu, and aim to build an "Integrated Biofoundry*4" that will provide one-stop service from microbial breeding to process development with JGC HD.

[ JGC HD ]
JGC HD has a profound knowledge of the safe gas handling of gases including hydrogen gas and process scale-up cultivated through its EPC (Engineering, Procurement, and Construction) business in the oil and gas fields, as well as in optimized culture tank design technology in the life science field. In this project, JGC HD will develop and scale-up a safe handling system for mixed gases containing CO2, H2, and O2 and a highly efficient gas fermentation process in addition to establishing an “Integrated Biofoundry” with Bacchus which will provide a one-stop service from microbial breeding to process development.

[ Shimadzu ]
Shimadzu, with the aim of solving social issues, has accumulated a variety of know-how by providing analytical measurement and robotics technologies to a wide range of fields and data analysis technologies using AI-based systems. In this project, Shimadzu will work on the development of high-speed productivity evaluation technology, which is indispensable for the construction of a biofoundry. Shimadzu will also develop an evaluation system to measure gas fermentation in the semi-commercial plant which is to be constructed as part of the project and support safe and highly efficient fermentation.

*1. A project to support companies and others working on management issues toward Japan's "Carbon Neutrality in 2050," from R&D and demonstration to social implementation by FY2030. The program covers 14 fields: transportation/manufacturing-related industries including carbon recycling/materials industries, energy-related industries, and home/office-related industries.
*2. Biofoundry: Microorganism development platform that creates microorganisms with designed functions to efficiently produce useful substances
*3. Smart cell: A cell that is highly designed and has an enhanced ability to efficiently produce the desired substance
*4. Integrated Biofoundry: A one-stop biomanufacturing platform that provides everything from microbial breeding to process development

To view this piece of content from, please give your consent at the top of this page.

Contact information

Investors & Public Relations Department
Chika Harada

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ilsong Educational Foundation Chairman Dai-Won Yoon Wins Linnaeus Medal as the First in Asia2.6.2023 11:00:00 CEST | Press release

On May 30, Chairman Dai-Won Yoon of Ilsong Educational Foundation received the Linnaeus Medal from Uppsala University at Hallym University. This makes him the first person from Asia to receive the award. Ilsong Educational Foundation operates Hallym University and Hallym University Medical Center. This press release features multimedia. View the full release here: Chairman Dai-Won Yoon (left) of Ilsong Educational Foundation received Linnaeus Medal as the 1st in Asia (Photo: Hallym University) Chairman Yoon is the honoree of 2020. The award ceremony, which had been postponed due to COVID-19, was held this year with a delegation led by Vice Chancellor Anders Hagfeldt of Uppsala University visiting Korea. The Linnaeus Medal to commemorate Carl Linnaeus, a Swedish botanist, is awarded annually by Uppsala University to a person who has made a significant contribution to the field of science. Chairman Yoon was honored for his work in

10 th Annual World Patient Safety, Science & Technology Summit Begins2.6.2023 08:15:00 CEST | Press release

Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare. This press release features multimedia. View the full release here: Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire) Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospit

Autel Energy Holds Partner Summit in Amsterdam, Mapping Out Europe Strategy2.6.2023 08:00:00 CEST | Press release

Autel Energy, a leading provider of EV charging products and services, successfully hosted the Autel Partner Summit at Muziekgebouw in Amsterdam from May 31 to June 1, 2023. The event not only showcased Autel’s visionary Europe strategy for the next two years but also provided partners opportunities to gain insights into the company's vision, and learn about Autel’s new products. This press release features multimedia. View the full release here: A quick afternoon bite with the Autel partners. (Photo: Business Wire) The Partner Summit helped Autel Energy to strengthen its partnerships in Europe and highlighted its collaborations with key clients. Notable partners in attendance included Maxicharger AC clients such as Sevadis and Deta, as well as Maxicharger DC clients such as Floading, Gasgas, and eWays. The company also partnered with CPO clients like Fastway and Powerdo, as well as energy companies like Enefit. The Summit was d

PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.2.6.2023 07:22:00 CEST | Press release

PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period. In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption. About PL BioScience: Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HP

AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera2.6.2023 04:00:00 CEST | Press release

With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA,PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s comp